Phase 3 N=199 A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Parkinson's Disease Psychosis
Primary: Antipsychotic Efficacy — -2.73; -5.79; NA; -3.06 Score on the SAPS-PD scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=45 A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
Break Through Pain · Cancer
Primary: Induction Phase: Pain Intensity Difference at 10 Minutes (PID10) After Treatment — 2.5; 1.4 units on a scale — p=0.002
Phase 3 N=495 A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
Major Depressive Disorder
Primary: Change From Baseline in MADRS Total Score at Week 8 — -16.53; -14.38 units on a scale — p=0.0018
Phase 3 N=298 A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Parkinson's Disease Psychosis
Primary: Antipsychotic Efficacy — -5.9; -5.8; -6.7; NA Score on the SAPS H+D scale
Phase 3 N=595 Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Hot Flashes
Primary: G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period…
Phase 3 N=1,117 Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 85.19; 65.45; -26.60; -20.52 units on a scale
Phase 3 N=337 Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) — -0.434; -0.587; 0.091 Percent of glycosylated hemoglobin — p=<0.001
Phase 3 N=520 A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers for the A/Turkey/Turkey/01/2005 (H5N1) Vaccine Strain. — 737.6; 24.7 Titer
Phase 3 N=374 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: SCR (Seroconversion Rate) at Day 56 — 41.2; 97.3; 25.6 percentage of participants — p=>0.99
Phase 3 N=529 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Meningococcal Disease
Primary: Percentage of Subjects With hSBA Titer ≥1:8 Against Serogroup A, C, W and Y One Month After Toddler Vaccination of MenACWY-CRM — 2; 1; 89; 2 Percentage of subjects
Phase 3 N=77 Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
Varicose Veins
Primary: The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks — 16.7; 30.7 units on a scale
Phase 3 N=1,010 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Survival — 10.0; 10.4 months — p=0.0007
Phase 3 N=4,545 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Meningitis, Meningococcal
Primary: Percentage of Subjects With hSBA Titer >=1:8 - US Subjects — 94; 72; 98; 90 Percentages of subjects
Phase 3 N=187 MOM Program 8-Year Follow-up
Child Development
Primary: Woodcock-Johnson Cognitive Ability Test, 3rd Edition (WJR-III, Cog) — 89.32; 87.62 units on a scale — p=0.39
Phase 3 N=1,901 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Bone Metastases
Primary: Time to the First On-Study SRE (Non-inferiority) — 521.0; 629.0 Days — p=0.0002